14-day Susceptibility-guided Bismuth Quadruple Therapy for Multiple Drug Resistant H. Pylori Infection
Key facts
- Who runs it
- National Cheng-Kung University Hospital
- Where
- Taiwan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 46 people enrolled
- Started
- 22 Aug 2022
- Ended
- 26 Jan 2024
- Type of study
- Interventional
- Treatments tested
- Bismuth-based susceptibility-guided treatment
- Record updated
- 13 November 2024
Who can take part
- Age
- 20 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- H. pylori-infected with treatment experience with at least one course of eradication failure
- H. pylori-infected with treatment naïve but having multiple-drug resistant H. pylori (>= three antibiotics)
- H. pylori infection confirmed by H. pylori culture
Who cannot take part
- Previous allergic reactions to regimens, including amoxicillin, bismuth subcitrate, esomeprazole, metronidazole, rifabutin, and tetracycline,
- Chronic kidney disease with estimated glomerular filtration rate < 60 ml/min/1.73 m2,
- Dual-resistant H. pylori infection
- Mono-resistant H. pylori infection
- All susceptible H. pylori infection
- Severe comorbidities,
- Pregnant or breastfeeding women
- Positive RUT but negative H. pylori culture
- Negative RUT and negative H. pylori culture
- Decline to participate
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn if the 14-day susceptibility-guided bismuth quadruple therapy works to treat multiple drug resistant Helicobacter pylori (H. pylori) in adults. It will also learn about the adverse effects of bismuth quadruple therapy. The main questions it aims to answer are:
Read full original descriptionShow less
* Does 14-day susceptibility-guided bismuth quadruple therapy higher the eradication rate? * What medical problems do participants have when taking 14-day susceptibility-guided bismuth quadruple? Researchers will record 14-day susceptibility-guided bismuth quadruple to see if 14-day susceptibility-guided bismuth quadruple works to treat multiple drug resistant H. pylori.
Participants will:
* Take susceptibility-guided bismuth quadruple every day for 14 days * Visit the clinic once 4-6 weeks for checkups and tests * Keep a diary of their symptoms during taking susceptibility-guided bismuth quadruple
The group in the trial
- Bismuth-based susceptibility-guided treatmentTreatment being tested
Participants who have triple- or quadruple-drug resistant H. pylori infection are enrolled. Participants receive one of the four regimens based on susceptibility test.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Study of Adding Bismuth on Susceptibility-based Regimen Strategy to Enhance the Eradication Rate for Multi-resistant H. Pylori Infection
- Record updated
- 13 November 2024